Byrd, John C <br/><br/>
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.  [electronic resource] 

 -  Blood  Jan 2010 
 - 489-95 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2009-08-237727  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Cyclophosphamide--administration & dosage<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Drug Resistance, Neoplasm--drug effects<br/>Female<br/>Humans<br/>Leukemia, Lymphocytic, Chronic, B-Cell--blood<br/>Male<br/>Middle Aged<br/>Recurrence<br/>Rituximab<br/>Vidarabine--administration & dosage